CD19 CAR-T治疗淋巴瘤中内源T细胞旁观效应的表型与功能变化
该研究在BALB/c小鼠模型中探讨CD19 CAR-T细胞治疗B细胞淋巴瘤时内源T细胞的旁观效应。体外实验显示CAR-T对CD19(-)A20细胞无特异性杀伤,但体内CAR-T治疗可缩小CD19(-)肿瘤并增加内源CD3(+)T细胞浸润。疾病复发后内源T细胞杀伤功能减弱并向静息及记忆表型转化。
要点
- CD19 CAR-T体内特异性杀伤可激活内源T细胞产生旁观效应,非特异性抑制淋巴瘤生长。
- 复发后内源CD8(+)T细胞比例下降趋势,CD69表达降低,细胞因子分泌减少。
- 复发期效应T细胞比例减少,初始及记忆T细胞比例增加。
核心结论
- CD19 CAR-T细胞体内特异性杀伤可激活内源T细胞产生旁观效应,非特异性抑制淋巴瘤生长。
- 疾病复发后内源T细胞杀伤功能逐渐减弱并向静息及记忆性表型转化。
研究设计与样本
- 在徐州医科大学血液病研究所利用BALB/c小鼠构建CD19 CAR-T治疗CD19(-)及CD19(+)A20淋巴瘤的体外和小鼠模型。
- 体外实验分活化T细胞组(n=3)和CD19 CAR-T细胞组(n=3)。
- CD19(-)A20小鼠模型分活化T细胞治疗组(n=5)和CD19 CAR-T治疗组(n=5)。
- CD19(+)A20小鼠模型分活化T细胞治疗组(n=3~8)、CD19 CAR-T治疗组(n=14)、缓解组(临床评分≤1分)和复发组(临床评分>1分)。
- 通过流式细胞术检测内源T细胞亚群、活化状态及细胞因子分泌。
主要发现
- 体外实验中CD19 CAR-T对CD19(-)A20细胞无特异性杀伤,存活率(40.83±1.70)%对(39.07±1.40)%,P=0.238。
- 免疫健全小鼠中CD19 CAR-T治疗较活化T细胞治疗使CD19(-)A20肿瘤重量减轻(0.14±0.10)g对(0.81±0.24)g,P=0.002,体积缩小(335.40±130.20)mm³对(542.00±302.40)mm³,P=0.004。
- CD19 CAR-T治疗后内源CD3(+)T细胞浸润比例更高(36.34±6.53)%对(9.49±9.42)%,P=0.001,CD69(+)CD8(+)T细胞比例更高(21.38±4.85)%对(3.15±1.16)%,P=0.001。
- CD19(+)A20模型中复发期较缓解期CD69表达强度降低:CD4(+)T细胞BM 733.20±274.40对1 093.00±131.20,P=0.013;SP 290.50±142.40对478.70±63.94,P=0.018;CD8(+)T细胞BM 1 223.00±391.50对1 892.00±540.40,P=0.041;SP 342.30±258.10对500.00±113.90,P=0.325。
- 复发期IFN-γ、TNF-α、GM-CSF、颗粒酶B分泌水平均下降(P值均<0.05),效应T细胞比例减少,初始及记忆T细胞比例增加(P值均<0.05)。
临床怎么用
- CD19 CAR-T治疗可通过激活内源T细胞旁观效应增强抗淋巴瘤作用。
- 疾病复发后内源T细胞功能耗竭并向记忆表型转化,提示需关注复发期免疫状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the bystander effect of endogenous T cells within the tumor microenvironment, as well as their roles and phenotypic changes during remission and relapse in mice with B-cell lymphoma receiving CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy. Methods: At the Institute of Hematology, Xuzhou Medical University, in vitro experiments and mouse models were established using BALB/c mice to evaluate the efficacy of CD19 CAR-T cells in treating CD19(-) and CD19(+)A20 lymphomas. In the in vitro experiments, the mice were categorized into the following groups based on the type of co-cultured cells: activated T cell (n=3) and CD19-targeted CAR-T cell (n=3) groups. In the CD19(-) A20 lymphoma mouse model, the mice were assigned to the activated T-cell (n=5) and CD19 CAR-T cell treatment (n=5) groups based on the type of cells used for treatment. For the CD19(+) A20 lymphoma mouse model, the mice were divided into the activated T cell treatment (n=3-8), CD19 CAR-T cell treatment (n=14), remission (clinical score ≤ 1), and relapse (clinical score >1) groups. Therapeutic efficacy was evaluated, and flow cytometry was used to analyze the subsets, activation status, and cytokine secretion profiles of endogenous T cells at different disease states. Results: In vitro experiments demonstrated that, compared with the activated T-cell group, CD19 CAR-T cells exerted no specific cytotoxic effect on CD19(-) A20 cells [survival rates: (40.83±1.70) %vs (39.07±1.40) %, P=0.238]. However, in immunocompetent mice, compared with the activated T-cell treatment, CD19-targeted CAR-T cell therapy resulted in reduced weight [ (0.14±0.10) vs (0.81±0.24) g, P=0.002] and significantly diminished subcutaneous CD19(-) A20 tumor volume [ (335.40±130.20) vs (542.00±302.40) mm(3), P=0.004], accompanied by increased infiltration of endogenous CD3(+) T cells [ (36.34±6.53) % vs (9.49±9.42) %, P=0.001]. CD8(+) T cells exhibited increased CD69 expression [ (21.38±4.85) % vs (3.15±1.16) %, P=0.001] and a trend toward decreased expression of exhaustion-associated molecules PD-1 and TIGIT (all P value >0.05). In the mouse model of CD19(+) A20 lymphoma remission and relapse, upon disease relapse, the proportion of endogenous CD8(+) T cells in the spleen (SP) and bone marrow (BM) showed a downward trend during disease relapse compared with that during the remission period, the CD69 expression intensity decreased (CD4(+) T cell: BM: 733.20±274.40 vs 1 093.00±131.20, P=0.013; SP: 290.50±142.40 vs 478.70±63.94, P=0.018; CD8(+) T cell: BM: 1 223.00±391.50 vs 1 892.00±540.40, P=0.041; SP: 342.30±258.10 vs 500.00±113.90, P=0.325) and the secretion levels of cytokines IFN-γ, TNF-α, GM-CSF, and granzyme B were all diminished (all P value <0.05). During relapse, the proportion of effector T cell (Teff) cells decreased significantly, whereas the proportions of naive T cell (Tn) cells and memory T cell (Tm) cells increased significantly (all P value <0.05) . Conclusion: The specific cytotoxic activity of CD19-targeted CAR-T cells in vivo can activate endogenous T cells and induce a bystander effect, which non-specifically inhibits lymphoma growth. However, following disease relapse, the cytotoxic function of endogenous T cells gradually diminishes and shifts toward resting and memory phenotypes. 目的: 探索肿瘤微环境中内源T细胞的旁观效应及其在CD19嵌合抗原受体T(CAR-T)细胞治疗B细胞淋巴瘤缓解及复发期中的作用及表型变化。 方法: 在徐州医科大学血液病研究所利用BALB/c小鼠构建CD19 CAR-T细胞治疗CD19(-)及CD19(+)A20淋巴瘤的体外和小鼠模型,其中体外实验根据共培养的细胞类型分为活化T细胞组(3只)和CD19 CAR-T细胞组(3只),CD19(-)A20淋巴瘤小鼠模型根据治疗的细胞类型分为活化T细胞治疗组(5只)和CD19 CAR-T细胞治疗组(5只);而CD19(+)A20淋巴瘤小鼠模型则依据治疗的细胞类型或疾病状态分为活化T细胞治疗组(3~8只)、CD19 CAR-T细胞治疗组(14只),缓解组(临床评分≤1分)和复发组(临床评分>1分),评估治疗效果并通过流式细胞术对不同疾病状态下内源T细胞的亚群、活化状态、细胞因子分泌情况进行检测。 结果: 体外实验表明,与活化T细胞组相比,CD19 CAR-T细胞对CD19(-)A20细胞无特异性杀伤作用[存活率:(40.83±1.70)%对(39.07±1.40)%,P=0.238];但在免疫健全的小鼠体内,相比于活化T细胞治疗组,CD19 CAR-T细胞治疗后CD19(-)A20皮下肿瘤的重量减轻[(0.14±0.10)g对(0.81±0.24)g,P=0.002]、体积显著缩小[(335.40±130.20)mm(3)对(542.00±302.40)mm(3),P=0.004],且内源CD3(+)T细胞浸润比例更高[(36.34±6.53)%对(9.49±9.42)%,P=0.001],CD69(+)CD8(+)T细胞比例更高[(21.38±4.85)%对(3.15±1.16)%,P=0.001],表达耗竭相关分子PD-1及TIGIT细胞比例呈下降趋势(P值均>0.05)。在CD19(+)A20淋巴瘤缓解和复发小鼠模型中,CD19 CAR-T细胞治疗复发后脾脏(SP)及骨髓(BM)中内源CD8(+)T细胞比例较缓解期呈下降趋势(P值均>0.05),CD69表达强度[平均荧光强度(MFI)]降低[CD4(+)T细胞:BM:733.20±274.40对1 093.00±131.20,P=0.013;SP:290.50±142.40对478.70±63.94,P=0.018;CD8(+)T细胞:BM:1 223.00±391.50对1 892.00±540.40,P=0.041;SP:342.30±258.10对500.00±113.90,P=0.325],细胞因子IFN-γ、TNF-α、GM-CSF、颗粒酶B的分泌水平均下降(P值均<0.05);复发期效应T细胞比例均明显减少,而初始T细胞及记忆T细胞比例明显增加(P值均<0.05)。 结论: CD19 CAR-T细胞体内的特异性杀伤可激活内源T细胞产生旁观效应,从而非特异性抑制淋巴瘤生长,但疾病复发后内源T细胞杀伤功能逐渐减弱并向静息及记忆性表型转化。.
引用
- Yan F, Tang DH, Li WW, et al. [Phenotypic and functional changes in endogenous T cells during the bystander effect in different disease states of lymphomas treated with CD19-targeted chimeric antigen receptor T cells]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851179. doi:10.3760/cma.j.cn121090-20260129-00066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。